Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) EBIT (2020 - 2025)

Journey Medical's EBIT history spans 6 years, with the latest figure at $5.3 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 139.08% year-over-year to $5.3 million, compared with a TTM value of -$2.4 million through Dec 2025, up 82.54%, and an annual FY2025 reading of -$2.4 million, up 82.54% over the prior year.
  • EBIT for Q4 2025 was $5.3 million at Journey Medical, up from -$1.5 million in the prior quarter.
  • The five-year high for EBIT was $17.2 million in Q3 2023, with the low at -$13.8 million in Q2 2021.
  • Average EBIT over 5 years is -$4.0 million, with a median of -$3.1 million recorded in 2024.
  • Year-over-year, EBIT plummeted 5391.21% in 2021 and then surged 281.68% in 2023.
  • Tracing DERM's EBIT over 5 years: stood at -$9.1 million in 2021, then fell by 10.36% to -$10.0 million in 2022, then skyrocketed by 78.95% to -$2.1 million in 2023, then soared by 206.18% to $2.2 million in 2024, then surged by 139.08% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's EBIT are $5.3 million (Q4 2025), -$1.5 million (Q3 2025), and -$2.9 million (Q2 2025).